BMS reports data that could give its cell therapy an edge over rival J&J product
Bristol Myers Squibb drug Abecma was the first FDA-approved CAR T-cell therapy for multiple myeloma, but like other drugs in
Read moreBristol Myers Squibb drug Abecma was the first FDA-approved CAR T-cell therapy for multiple myeloma, but like other drugs in
Read moreIf the 12 states that have not expanded Medicaid eligibility under the Affordable Care Act did so, 3.7 million people
Read moreThe latest–and perhaps final–blow to the once-promising Alzheimer’s Disease medication Aduhelm came when its maker, Biogen, said it will stop
Read moreOne reason engineered viruses are used to deliver genetic medicines is that viruses are very good at getting into cells.
Read moreIn a recent webinar, Carta Healthcare CEO Matt Hollingsworth shared how his health tech business is using AI for data
Read moreIn the past decade, large health systems such as Mayo Clinic, Kaiser Permanente and Ascension have been launching internal investment
Read moreSCAN Health Plan, a Medicare Advantage insurer, will begin offering health plans in two Texas counties and grow its services
Read moreCommercial health plans use practices that delay patient care and raise administrative costs, a recent report by the American Hospital
Read moreThere’s a severe evidence gap in healthcare treatment guidelines. Clinical trials shape most care guidelines and payer decisions, yet they
Read moreAs the saying goes, “You can’t make a second first impression.” And in no industry does a first impression carry
Read more